文献速递胸部肿瘤

LIBELULE:评估早期液体活检对疑似转移性肺癌患者临床相关性的随机III期研究

LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2024-12-16

该III期随机试验纳入319例影像学疑似晚期肺癌患者,1:1分为液体活检组(161例)和对照组(158例)。主要终点为随机化至基于可提供信息的基因组和病理结果启动适当治疗的时间(TTI),液体活检组平均TTI为29.0天,对照组为34天(p=0.26),差异未达统计学显著。亚组分析显示,在接受全身治疗、晚期非鳞状NSCLC及一线可靶向变异患者中,液体活检组TTI较短。

要点

  • 在未选择的疑似晚期肺癌患者中,早期液体活检未显著缩短至适当治疗启动时间(29.0天 vs 34天,p=0.26)。
  • 接受全身治疗患者中,液体活检组TTI为29.1天,对照组为38.9天(p=0.01)。
  • 晚期非鳞状NSCLC患者中,液体活检组TTI为29.5天,对照组为40.3天(p=0.01)。

核心结论

  • 早期液体活检未显著缩短未选择的疑似晚期肺癌患者的至适当治疗启动时间。
  • 在适合全身治疗的患者中,尤其是一线可靶向变异患者,液体活检可能缩短TTI。

研究设计与样本

  • III期随机对照试验(NCT03721120),纳入319例影像学疑似晚期肺癌患者,1:1随机分为液体活检组(161例)和对照组(158例)。
  • 对照组按各中心实践接受诊断性操作,液体活检组在首次就诊时额外使用InVisionFirst-Lung检测进行液体活检。
  • 治疗启动及类型依据欧洲肿瘤内科学会指南定义,主要终点为意向治疗人群中基于可提供信息的基因组和病理结果启动适当治疗的时间。

主要发现

  • 液体活检组81%的患者检出循环肿瘤DNA。
  • 平均TTI未显著缩短:液体活检组29.0天,对照组34天(p=0.26)。
  • 接受全身治疗患者中,液体活检组TTI为29.1天,对照组为38.9天(p=0.01)。
  • 晚期非鳞状NSCLC患者中,液体活检组TTI为29.5天,对照组为40.3天(p=0.01)。
  • 一线可靶向变异患者中,液体活检组TTI为21天,对照组为37.4天(p=0.004);至可提供信息的基因组结果时间显著缩短:液体活检组17.9天,对照组25.6天(p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Genomic profiling is a major component for first-line treatment decisions in patients with NSCLC and the timeliness of biomarker testing is essential to improve time to treatment initiation (TTI) or avoid inappropriate treatment. METHODS: The phase III LIquid Biopsy for the Early detection of LUng cancer Lesion trial (NCT03721120) included patients with radiological suspicion of advanced lung cancer. They were randomized (1:1), the control arm receiving diagnostic procedures according to each center's practice, and the liquid biopsy arm with additional testing performed at the first visit using the InVisionFirst-Lung assay. Treatment initiation and type were defined according to the European Society for Medical Oncology guidelines. Primary endpoint was the time from randomization to initiation of appropriate treatment on the basis of informative genomic and pathological results in the intention-to-treat population. RESULTS: A total of 319 patients were enrolled (liquid biopsy [LB]: 161; control: 158). The median age was 68 years, 28.8% were non-smokers, 18.1% had a performance status of 2 or higher, and 56.7% had adenocarcinoma. In the LB arm, 81% of patients had circulating tumor DNA findings. The mean TTI was not significantly reduced (LB: 29.0 d; control 34 d (p = 0.26)). Sensitivity analyses found a shorter TTI in patients from the LB arm who received systemic treatment (LB: 29.1 d; control: 38.9 d, p = 0.01), in patients with advanced non-squamous NSCLC (LB: 29.5 d; control: 40.3 d, p = 0.01), and in patients with first-line targetable alterations (LB: 21d; control 37.4 d) (p = 0.004). Time to contributory genomic results was significantly reduced (LB: 17.9 d; control: 25.6 d, p < 0.001). CONCLUSION: Early liquid biopsy testing did not significantly shorten the TTI in unselected patients referred for suspected advanced lung cancer. Nevertheless, it could reduce the TTI in patients eligible for systemic treatment, particularly for those with actionable alterations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Swalduz A, Schiffler C, Curcio H, et al. LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer. J Thorac Oncol. 2024. PMID: 39694415. doi:10.1016/j.jtho.2024.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。